-
Elon Musk Says His Neuralink Chip Could Treat Paralysis, Stroke And Brain Injury
Sunday, April 24, 2022 - 12:43pm | 648Read More...Tesla Inc (NASDAQ: TSLA) CEO Elon Musk's startup Neuralink brain chip could help treat morbid obesity; that's what Musk believes. Echoing Musk's statement, scientists say it's not an impossibility. Responding to a Twitter post on the same line, Musk said that it is...
-
UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition
Tuesday, June 22, 2021 - 12:47pm | 204Read More...UniQure N.V. (NASDAQ: QURE) has agreed to acquire Corlieve Therapeutics and its lead program for temporal lobe epilepsy (TLE), the most common form of focal epilepsy. The company will pay €46.3 million in an upfront cash payment. Corlieve shareholders are eligible to receive up...
-
CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases
Tuesday, June 15, 2021 - 8:06am | 236Read More...CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a delivery mechanism for the company’s gene-editing technology in familial amyotrophic lateral sclerosis (ALS) and rare...
-
Bluebird bio's Neurological Disorder Gene Therapy Wins CHMP Backing for Approval
Friday, May 21, 2021 - 10:51am | 236Read More...The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc’s (NASDAQ: BLUE) Skysona (elivaldogene autotemcel) new gene therapy for children with a rare, inherited neurological...
-
Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions
Monday, April 19, 2021 - 9:16am | 330Read More...Ovid Therapeutics Inc (NASDAQ: OVID) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The company says that while OV101 was well tolerated, with no significant...
-
Anima Attracts Takeda In Multibillion-Dollar mRNA Translation Modulators Deal For Neurological Diseases
Thursday, March 18, 2021 - 12:09pm | 539Read More...Small-molecule mRNA translation Israeli firm Anima Biotech Inc has landed a new research deal with Takeda Pharmaceutical Co Ltd (NYSE: TAK), covering as many as six programs for genetically-defined neurological diseases. Two-part collaboration could hold as much...
-
Acorda Therapeutics To Acquire Biotie Therapies To Boost Its Parkinson's Disease Therapeutic Development
Tuesday, January 19, 2016 - 10:40am | 322Read More...Acorda Therapeutics Inc (NASDAQ: ACOR), a biopharmaceutical company that develops therapies for neurological disorders, on Tuesday announced that it has acquired Biotie Therapies Oyj (ADR) (NASDAQ: BITI) for $25.60 per ADS. Biotie Therapies is a Finland-based drug development company...
